These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 30389797)

  • 1.
    Wang B; Zhang W; Jankovic V; Golubov J; Poon P; Oswald EM; Gurer C; Wei J; Ramos I; Wu Q; Waite J; Ni M; Adler C; Wei Y; Macdonald L; Rowlands T; Brydges S; Siao J; Poueymirou W; MacDonald D; Yancopoulos GD; Sleeman MA; Murphy AJ; Skokos D
    Sci Immunol; 2018 Nov; 3(29):. PubMed ID: 30389797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD226
    Jin HS; Ko M; Choi DS; Kim JH; Lee DH; Kang SH; Kim I; Lee HJ; Choi EK; Kim KP; Yoo C; Park Y
    Cancer Immunol Res; 2020 Jul; 8(7):912-925. PubMed ID: 32265229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-15-dependent upregulation of GITR on CD8 memory phenotype T cells in the bone marrow relative to spleen and lymph node suggests the bone marrow as a site of superior bioavailability of IL-15.
    Snell LM; Lin GH; Watts TH
    J Immunol; 2012 Jun; 188(12):5915-23. PubMed ID: 22581858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
    Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
    Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
    Leyland R; Watkins A; Mulgrew KA; Holoweckyj N; Bamber L; Tigue NJ; Offer E; Andrews J; Yan L; Mullins S; Oberst MD; Coates Ulrichsen J; Leinster DA; McGlinchey K; Young L; Morrow M; Hammond SA; Mallinder P; Herath A; Leow CC; Wilkinson RW; Stewart R
    Clin Cancer Res; 2017 Jul; 23(13):3416-3427. PubMed ID: 28069723
    [No Abstract]   [Full Text] [Related]  

  • 7. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.
    Berhanu A; Huang J; Watkins SC; Okada H; Storkus WJ
    J Immunol; 2007 Mar; 178(6):3400-8. PubMed ID: 17339434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GITR Agonism Enhances Cellular Metabolism to Support CD8
    Sabharwal SS; Rosen DB; Grein J; Tedesco D; Joyce-Shaikh B; Ueda R; Semana M; Bauer M; Bang K; Stevenson C; Cua DJ; Zúñiga LA
    Cancer Immunol Res; 2018 Oct; 6(10):1199-1211. PubMed ID: 30154083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner.
    Charlton JJ; Chatzidakis I; Tsoukatou D; Boumpas DT; Garinis GA; Mamalaki C
    J Immunol; 2013 Jun; 190(12):6104-14. PubMed ID: 23686498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
    Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
    J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of anti-GITR-based combination immunotherapy.
    Zappasodi R; Sirard C; Li Y; Budhu S; Abu-Akeel M; Liu C; Yang X; Zhong H; Newman W; Qi J; Wong P; Schaer D; Koon H; Velcheti V; Hellmann MD; Postow MA; Callahan MK; Wolchok JD; Merghoub T
    Nat Med; 2019 May; 25(5):759-766. PubMed ID: 31036879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
    Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
    Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
    Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
    Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
    Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
    Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
    Johnston RJ; Comps-Agrar L; Hackney J; Yu X; Huseni M; Yang Y; Park S; Javinal V; Chiu H; Irving B; Eaton DL; Grogan JL
    Cancer Cell; 2014 Dec; 26(6):923-937. PubMed ID: 25465800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR.
    Mizuno R; Maruhashi T; Sugiura D; Shimizu K; Watada M; Okazaki IM; Okazaki T
    Biochem Biophys Res Commun; 2019 Apr; 511(3):491-497. PubMed ID: 30771904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.
    Villarreal DO; Chin D; Smith MA; Luistro LL; Snyder LA
    Oncotarget; 2017 Jun; 8(24):39117-39130. PubMed ID: 28388572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.